- GBI & PARTNERS
- Apeloa Pharma's Keppra generic gets market nod in China
Apeloa Pharma's Keppra generic gets market nod in China
China-based Apeloa Pharmaceutical Co., Ltd, (000739) announced market approval from the National Medical Products Administration (NMPA) for its generic version of the anti-epilepsy therapy levetiracetam. The market filing for said drug, the company’s first product to pass generic quality consistency evaluation (GQCE) testing, was made in February 2018.
Levetiracetam was originally developed by Belgium-based UCB, marketed under the brand name Keppra, and gained a first global approval in the US in 1999. UCB brought the drug to China in 2006, and it has reportedly generated RMB 1 billion (USD 140 million) in local sales since then.